罗拉匹坦与合并用药在II/III期试验中的整合安全性分析:评估罗拉匹坦对CYP2D6或BCRP的抑制作用
四项双盲随机II/III期试验的整合安全性分析评估罗拉匹坦与CYP2D6或BCRP底物药物合用的不良事件。罗拉匹坦组828/1294例(64%)和对照组840/1301例(65%)发生至少一次治疗中出现的不良事件,常见不良事件频率相似,无论是否合用CYP2D6或BCRP底物药物,不良事件和严重不良事件频率均相似。结果支持罗拉匹坦作为止吐三联方案组成部分的安全性。
要点
- 罗拉匹坦组64%(828/1294)与对照组65%(840/1301)发生至少一次治疗中出现的不良事件,常见不良事件频率相似。
- 53%患者合用CYP2D6底物药物(无窄治疗指数药物),63%合用BCRP底物药物。
- 按是否合用CYP2D6或BCRP底物药物分组,罗拉匹坦组与对照组不良事件和严重不良事件频率相似。
核心结论
- 结果支持罗拉匹坦作为止吐三联方案组成部分在接受致吐性化疗患者中的安全性,包括合用CYP2D6或BCRP底物药物(如昂丹司琼、多西他赛或伊立替康)者。
研究设计与样本
- 四项双盲、随机II期或III期研究的整合安全性分析。
- 患者随机接受180 mg口服罗拉匹坦或安慰剂,化疗前约1-2小时给药,联用5-羟色胺3型受体拮抗剂和地塞米松。
- 汇总第1周期治疗中出现的不良事件(TEAEs)和治疗中出现的严重不良事件(TESAEs)数据,按是否合用CYP2D6或BCRP底物药物分组总结。
主要发现
- 罗拉匹坦组828/1294例(64%)和对照组840/1301例(65%)发生至少一次TEAE。
- 罗拉匹坦组与对照组常见TEAE频率相似。
- 53%患者合用CYP2D6底物药物,均无窄治疗指数药物(如硫利达嗪或匹莫齐特);63%患者合用BCRP底物药物。
- 按是否合用CYP2D6或BCRP底物药物分组,罗拉匹坦组与对照组TEAE和TESAE频率相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rolapitant, a long-acting neurokinin (NK)1 receptor antagonist (RA), has demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in patients administered moderately or highly emetogenic chemotherapy. Unlike other NK1 RAs, rolapitant does not inhibit or induce cytochrome P450 (CYP) 3A4, but it does inhibit CYP2D6 and breast cancer resistance protein (BCRP). To analyze potential drug-drug interactions between rolapitant and concomitant medications, this integrated safety analysis of four double-blind, randomized phase II or III studies of rolapitant examined adverse events (AEs) by use versus non-use of drug substrates of CYP2D6 or BCRP. PATIENTS AND METHODS: Patients were randomized to receive either 180 mg oral rolapitant or placebo ∼1-2 h before chemotherapy in combination with a 5-hydroxytryptamine type 3 RA and dexamethasone. Data for treatment-emergent AEs (TEAEs) and treatment-emergent serious AEs (TESAEs) during cycle 1 were pooled across the four studies and summarized in the overall population and by concomitant use/non-use of CYP2D6 or BCRP substrate drugs. RESULTS: In the integrated safety population, 828 of 1294 patients (64%) in the rolapitant group and 840 of 1301 patients (65%) in the control group experienced at least one TEAE. Frequencies of common TEAEs were similar in the rolapitant and control populations. Overall, 53% of patients received CYP2D6 substrate drugs, none of which had a narrow therapeutic index (like thioridazine or pimozide), and 63% received BCRP substrate drugs. When grouped by concomitant use versus non-use of CYP2D6 or BCRP substrate drugs, TEAEs and TESAEs occurred with similar frequency in the rolapitant and control populations. CONCLUSIONS: The results of this study support the safety of rolapitant as part of an antiemetic triple-drug regimen in patients receiving emetogenic chemotherapy, including those administered concomitant medications that are substrates of CYP2D6 or BCRP, such as ondansetron, docetaxel, or irinotecan.
引用
- Barbour S, Smit T, Wang X, et al. Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant. Ann Oncol. 2017. PMID: 28327932. doi:10.1093/annonc/mdx073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。